Abstract
This study evaluated occurrence and potential clinical significance of intratumoral EGFR mutational heterogeneity in Chinese patients with non-small cell lung cancer (NSCLC). Eighty-five stage IIIa-IV NSCLC patients who had undergone palliative surgical resection were included in this study. Of these, 45 patients carried EGFR mutations (group-M) and 40 patients were wild-type (group-W). Each tumor sample was microdissected to yield 28-34 tumor foci and Intratumoral EGFR mutation were determined using Denaturing High Performance Liquid Chromatography (DHPLC) and Amplification Refractory Mutation System (ARMS). EGFR copy numbers were measured using fluorescence in situ hybridization (FISH). Microdissection yielded 1,431 tumor foci from EGFR mutant patients (group-M) and 1,238 foci from wild-type patients (group-W). The EGFR mutant frequencies in group-M were 80.6% (1,154/1,431) and 87.1% (1,247/1,431) using DHPLC and ARMS, respectively. A combination of EGFR-mutated and wild-type cells was detected in 32.9% (28/85) of samples by DHPLC and 28.2% (24/85) by ARMS, supporting the occurrence of intratumoral heterogeneity. Thirty-one patients (36.5%) were identified as EGFR FISH-positive. Patients harboring intratumoral mutational heterogeneity possessed lower EGFR copy numbers than those tumors contained mutant cells alone (16.7% vs. 71.0%, P<0.05). Among 26 patients who had received EGFR-TKIs, the mean EGFR mutation content was higher in patients showing partial response (86.1%) or stable disease (48.7%) compared with patients experiencing progressive disease (6.0%) (P = 0.001). There also showed relationship between progression-free survival (PFS) and different content of EGFR mutation groups (pure wild type EGFR, EGFR mutation with heterogeneity and pure mutated EGFR) (P = 0.001). Approximately 30% of patients presented intratumoral EGFR mutational heterogeneity, accompanying with relatively low EGFR copy number. EGFR mutant content was correlated with the response and prognosis of EGFR-TKIs.
MeSH Terms
Adult
Aged
Aged, 80 and over
Asians/genetics
Biomarkers, Tumor/genetics
Carcinoma, Non-Small-Cell Lung/drug therapy,genetics,pathology
China
DNA Mutational Analysis
Disease-Free Survival
ErbB Receptors/genetics
Female
Humans
Lung Neoplasms/drug therapy,genetics,pathology
Male
Middle Aged
Mutation
Prognosis
Protein Kinase Inhibitors/therapeutic use
Treatment Outcome
Chemicals
Biomarkers, Tumor
Protein Kinase Inhibitors
EGFR protein, human
ErbB Receptors
Authors & Affiliations
11 authors, click to expand affiliations / ORCID
Bai Hua
Key Laboratory of Carcinogenesis and Translational Research Ministry of Education, Department of Thoracic Medical Oncology, Peking University Cancer Hospital & Institute, Beijing, China.
Wang Zhijie
Wang Yuyan
Zhuo Minglei
Zhou Qinghua
Duan Jianchun
Yang Lu
Wu Meina
An Tongtong
Zhao Jun
Wang Jie
References (31)
31 references, click to expand
-
Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma.
Cancer Cell. 2011 Dec 13;20(6):810-7
PMID: 22137795
-
Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.
J Clin Oncol. 2011 Aug 1;29(22):2972-7
PMID: 21730270
-
Influence of chemotherapy on EGFR mutation status among patients with non-small-cell lung cancer.
J Clin Oncol. 2012 Sep 1;30(25):3077-83
PMID: 22826274
-
Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.
N Engl J Med. 2012 Mar 8;366(10):883-892
PMID: 22397650
-
Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer.
Cancer. 2006 Dec 15;107(12):2858-65
PMID: 17096434
-
The new World Health Organization classification of lung tumours.
Eur Respir J. 2001 Dec;18(6):1059-68
PMID: 11829087
-
Molecular evolution and intratumor heterogeneity by topographic compartments in muscle-invasive transitional cell carcinoma of the urinary bladder.
Lab Invest. 2000 Mar;80(3):279-89
PMID: 10744064
-
Genetic heterogeneity and cancer drug resistance.
Lancet Oncol. 2012 Apr;13(4):e178-85
PMID: 22469128
-
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Science. 2004 Jun 4;304(5676):1497-500
PMID: 15118125
-
Evidence of independent origin of multiple tumors from patients with prostate cancer.
J Natl Cancer Inst. 1998 Feb 4;90(3):233-7
PMID: 9462681
-
Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas.
Dis Esophagus. 2007;20(1):9-11
PMID: 17227303
-
Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer.
Clin Cancer Res. 2010 Nov 15;16(22):5489-98
PMID: 21062933
-
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
J Clin Oncol. 2007 Feb 10;25(5):587-95
PMID: 17290067
-
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
J Natl Cancer Inst. 2005 May 4;97(9):643-55
PMID: 15870435
-
Genetic heterogeneity in ductal carcinoma of the breast.
Lab Invest. 2000 Mar;80(3):291-301
PMID: 10744065
-
Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
J Clin Oncol. 2009 Jun 1;27(16):2653-9
PMID: 19414683
-
Personalized targeted therapy for lung cancer.
Int J Mol Sci. 2012;13(9):11471-96
PMID: 23109866
-
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11
PMID: 15329413
-
Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.
Cancer Sci. 2008 May;99(5):929-35
PMID: 18325048
-
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
J Clin Invest. 2008 Jul;118(7):2609-19
PMID: 18568074
-
Mechanisms of tumor progression.
Cancer Res. 1986 May;46(5):2203-7
PMID: 3516380
-
Cancer stem cells: impact, heterogeneity, and uncertainty.
Cancer Cell. 2012 Mar 20;21(3):283-96
PMID: 22439924
-
Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.
Lung Cancer. 2008 Jun;60 Suppl 2:S3-9
PMID: 18513582
-
EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples.
J Clin Pathol. 2013 Feb;66(2):79-89
PMID: 23172555
-
The new lung cancer staging system.
Chest. 2009 Jul;136(1):260-271
PMID: 19584208
-
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
PLoS Med. 2005 Mar;2(3):e73
PMID: 15737014
-
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
N Engl J Med. 2004 May 20;350(21):2129-39
PMID: 15118073
-
Epidermal growth factor receptor mutations in female patients with postoperative recurrent non-small-cell lung cancer.
J Cancer Res Ther. 2012 Jul-Sep;8(3):373-8
PMID: 23174717
-
Detection of epidermal growth factor receptor variations by partially denaturing HPLC.
Clin Chem. 2007 Jan;53(1):62-70
PMID: 17110474
-
Metapopulation dynamics and spatial heterogeneity in cancer.
Proc Natl Acad Sci U S A. 2002 Oct 1;99(20):13085-9
PMID: 12351679
-
Which biomarker predicts benefit from EGFR-TKI treatment for patients with lung cancer?
Br J Cancer. 2007 Mar 26;96(6):857-63
PMID: 17325698